Drug Facts
Composition & Profile
Identifiers & Packaging
16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied SIGNIFOR LAR for injectable suspension is supplied in a single-use kit containing the following: One 6-mL brownish glass vial with a grey rubber stopper of SIGNIFOR LAR containing slightly yellow to yellow powder with a flip-off cap One 3-mL glass barrel/grey rubber stopper prefilled syringe containing 2 mL of clear, colorless to slightly yellow/brown diluent solution for reconstitution One sterile 20G x 1.5" stainless steel, polypropylene safety injection needle One vial adapter made of polycarbonate for drug product reconstitution SIGNIFOR LAR kits are available in the following strengths: SIGNIFOR LAR Kit Final Concentration When Reconstituted (total product strength per total volume) Final Concentration When Reconstituted (per mL) Flip-off Cap Color NDC 10 mg 10 mg/2 mL 5 mg/mL Brown 55292-139-01 20 mg 20 mg/2 mL 10 mg/mL Gray 55292-140-01 30 mg 30 mg/2 mL 15 mg/mL Lilac 55292-141-01 40 mg 40 mg/2 mL 20 mg/mL Red 55292-142-01 60 mg 60 mg/2 mL 30 mg/mL Orange 55292-143-01 16.2 Storage and Handling Store at 2°C to 8°C (36°F-46°F). Do not freeze. SIGNIFOR LAR should be stored at refrigerated temperatures between 2°C to 8°C (36°F-46°F) until the time of use. SIGNIFOR LAR drug product kit should remain at room temperature for a minimum of 30 minutes before reconstitution, but should not exceed 24 hours at room temperature. However, after preparation of the drug suspension, it must be administered immediately.; 16.1 How Supplied SIGNIFOR LAR for injectable suspension is supplied in a single-use kit containing the following: One 6-mL brownish glass vial with a grey rubber stopper of SIGNIFOR LAR containing slightly yellow to yellow powder with a flip-off cap One 3-mL glass barrel/grey rubber stopper prefilled syringe containing 2 mL of clear, colorless to slightly yellow/brown diluent solution for reconstitution One sterile 20G x 1.5" stainless steel, polypropylene safety injection needle One vial adapter made of polycarbonate for drug product reconstitution SIGNIFOR LAR kits are available in the following strengths: SIGNIFOR LAR Kit Final Concentration When Reconstituted (total product strength per total volume) Final Concentration When Reconstituted (per mL) Flip-off Cap Color NDC 10 mg 10 mg/2 mL 5 mg/mL Brown 55292-139-01 20 mg 20 mg/2 mL 10 mg/mL Gray 55292-140-01 30 mg 30 mg/2 mL 15 mg/mL Lilac 55292-141-01 40 mg 40 mg/2 mL 20 mg/mL Red 55292-142-01 60 mg 60 mg/2 mL 30 mg/mL Orange 55292-143-01; 16.2 Storage and Handling Store at 2°C to 8°C (36°F-46°F). Do not freeze. SIGNIFOR LAR should be stored at refrigerated temperatures between 2°C to 8°C (36°F-46°F) until the time of use. SIGNIFOR LAR drug product kit should remain at room temperature for a minimum of 30 minutes before reconstitution, but should not exceed 24 hours at room temperature. However, after preparation of the drug suspension, it must be administered immediately.; PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 139 01 NDC 55292 139 01 Signifor ® LAR (pasireotide) For Injectable Suspension For Intramuscular Use Should only be administered by a trained health care professional. Remove the injection kit from the refrigerator and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours. RECORDATI RARE DISEASES GROUP Rx only 10 mg Each carton contains: One vial containing Signifor ® LAR powder One prefilled syringe containing diluent solution for reconstitution One vial adapter for drug product reconstitution One 20G x 1.5" safety injection needle PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 139 01; PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 140 01 NDC 55292 140 01 Signifor ® LAR (pasireotide) For Injectable Suspension For Intramuscular Use Should only be administered by a trained health care professional. Remove the injection kit from the refrigerator and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours. RECORDATI RARE DISEASES GROUP Rx only 20 mg Each carton contains: One vial containing Signifor ® LAR powder One prefilled syringe containing diluent solution for reconstitution One vial adapter for drug product reconstitution One 20G x 1.5" safety injection needle PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 140 01; PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 141 01 NDC 55292 141 01 Signifor ® LAR (pasireotide) For Injectable Suspension For Intramuscular Use Should only be administered by a trained health care professional. Remove the injection kit from the refrigerator and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours. RECORDATI RARE DISEASES GROUP Rx only 30 mg Each carton contains: One vial containing Signifor ® LAR powder One prefilled syringe containing diluent solution for reconstitution One vial adapter for drug product reconstitution One 20G x 1.5" safety injection needle PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 141 01; PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 142 01 NDC 55292 142 01 Signifor ® LAR (pasireotide) For Injectable Suspension For Intramuscular Use Should only be administered by a trained health care professional. Remove the injection kit from the refrigerator and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours. RECORDATI RARE DISEASES GROUP Rx only 40 mg Each carton contains: One vial containing Signifor ® LAR powder One prefilled syringe containing diluent solution for reconstitution One vial adapter for drug product reconstitution One 20G x 1.5" safety injection needle PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 142 01; PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 143 01 NDC 55292 143 01 Signifor ® LAR (pasireotide) For Injectable Suspension For Intramuscular Use Should only be administered by a trained health care professional. Remove the injection kit from the refrigerator and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours. RECORDATI RARE DISEASES GROUP Rx only 60 mg Each carton contains: One vial containing Signifor ® LAR powder One prefilled syringe containing diluent solution for reconstitution One vial adapter for drug product reconstitution One 20G x 1.5" safety injection needle PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 143 01
- 16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied SIGNIFOR LAR for injectable suspension is supplied in a single-use kit containing the following: One 6-mL brownish glass vial with a grey rubber stopper of SIGNIFOR LAR containing slightly yellow to yellow powder with a flip-off cap One 3-mL glass barrel/grey rubber stopper prefilled syringe containing 2 mL of clear, colorless to slightly yellow/brown diluent solution for reconstitution One sterile 20G x 1.5" stainless steel, polypropylene safety injection needle One vial adapter made of polycarbonate for drug product reconstitution SIGNIFOR LAR kits are available in the following strengths: SIGNIFOR LAR Kit Final Concentration When Reconstituted (total product strength per total volume) Final Concentration When Reconstituted (per mL) Flip-off Cap Color NDC 10 mg 10 mg/2 mL 5 mg/mL Brown 55292-139-01 20 mg 20 mg/2 mL 10 mg/mL Gray 55292-140-01 30 mg 30 mg/2 mL 15 mg/mL Lilac 55292-141-01 40 mg 40 mg/2 mL 20 mg/mL Red 55292-142-01 60 mg 60 mg/2 mL 30 mg/mL Orange 55292-143-01 16.2 Storage and Handling Store at 2°C to 8°C (36°F-46°F). Do not freeze. SIGNIFOR LAR should be stored at refrigerated temperatures between 2°C to 8°C (36°F-46°F) until the time of use. SIGNIFOR LAR drug product kit should remain at room temperature for a minimum of 30 minutes before reconstitution, but should not exceed 24 hours at room temperature. However, after preparation of the drug suspension, it must be administered immediately.
- 16.1 How Supplied SIGNIFOR LAR for injectable suspension is supplied in a single-use kit containing the following: One 6-mL brownish glass vial with a grey rubber stopper of SIGNIFOR LAR containing slightly yellow to yellow powder with a flip-off cap One 3-mL glass barrel/grey rubber stopper prefilled syringe containing 2 mL of clear, colorless to slightly yellow/brown diluent solution for reconstitution One sterile 20G x 1.5" stainless steel, polypropylene safety injection needle One vial adapter made of polycarbonate for drug product reconstitution SIGNIFOR LAR kits are available in the following strengths: SIGNIFOR LAR Kit Final Concentration When Reconstituted (total product strength per total volume) Final Concentration When Reconstituted (per mL) Flip-off Cap Color NDC 10 mg 10 mg/2 mL 5 mg/mL Brown 55292-139-01 20 mg 20 mg/2 mL 10 mg/mL Gray 55292-140-01 30 mg 30 mg/2 mL 15 mg/mL Lilac 55292-141-01 40 mg 40 mg/2 mL 20 mg/mL Red 55292-142-01 60 mg 60 mg/2 mL 30 mg/mL Orange 55292-143-01
- 16.2 Storage and Handling Store at 2°C to 8°C (36°F-46°F). Do not freeze. SIGNIFOR LAR should be stored at refrigerated temperatures between 2°C to 8°C (36°F-46°F) until the time of use. SIGNIFOR LAR drug product kit should remain at room temperature for a minimum of 30 minutes before reconstitution, but should not exceed 24 hours at room temperature. However, after preparation of the drug suspension, it must be administered immediately.
- PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 139 01 NDC 55292 139 01 Signifor ® LAR (pasireotide) For Injectable Suspension For Intramuscular Use Should only be administered by a trained health care professional. Remove the injection kit from the refrigerator and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours. RECORDATI RARE DISEASES GROUP Rx only 10 mg Each carton contains: One vial containing Signifor ® LAR powder One prefilled syringe containing diluent solution for reconstitution One vial adapter for drug product reconstitution One 20G x 1.5" safety injection needle PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 139 01
- PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 140 01 NDC 55292 140 01 Signifor ® LAR (pasireotide) For Injectable Suspension For Intramuscular Use Should only be administered by a trained health care professional. Remove the injection kit from the refrigerator and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours. RECORDATI RARE DISEASES GROUP Rx only 20 mg Each carton contains: One vial containing Signifor ® LAR powder One prefilled syringe containing diluent solution for reconstitution One vial adapter for drug product reconstitution One 20G x 1.5" safety injection needle PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 140 01
- PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 141 01 NDC 55292 141 01 Signifor ® LAR (pasireotide) For Injectable Suspension For Intramuscular Use Should only be administered by a trained health care professional. Remove the injection kit from the refrigerator and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours. RECORDATI RARE DISEASES GROUP Rx only 30 mg Each carton contains: One vial containing Signifor ® LAR powder One prefilled syringe containing diluent solution for reconstitution One vial adapter for drug product reconstitution One 20G x 1.5" safety injection needle PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 141 01
- PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 142 01 NDC 55292 142 01 Signifor ® LAR (pasireotide) For Injectable Suspension For Intramuscular Use Should only be administered by a trained health care professional. Remove the injection kit from the refrigerator and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours. RECORDATI RARE DISEASES GROUP Rx only 40 mg Each carton contains: One vial containing Signifor ® LAR powder One prefilled syringe containing diluent solution for reconstitution One vial adapter for drug product reconstitution One 20G x 1.5" safety injection needle PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 142 01
- PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 143 01 NDC 55292 143 01 Signifor ® LAR (pasireotide) For Injectable Suspension For Intramuscular Use Should only be administered by a trained health care professional. Remove the injection kit from the refrigerator and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours. RECORDATI RARE DISEASES GROUP Rx only 60 mg Each carton contains: One vial containing Signifor ® LAR powder One prefilled syringe containing diluent solution for reconstitution One vial adapter for drug product reconstitution One 20G x 1.5" safety injection needle PRINCIPAL DISPLAY PANEL - Kit Carton - NDC 55292 143 01
Overview
SIGNIFOR LAR (pasireotide) for injectable suspension is a long-acting release form of pasireotide pamoate, as powder to be suspended in the provided diluent immediately prior to intramuscular injection. SIGNIFOR LAR contains pasireotide, a somatostatin analog in the form of pasireotide pamoate (pamoic acid salt). Pasireotide is a cyclohexapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Pasireotide pamoate has a chemical name of (2-Aminoethyl) carbamic acid (2R,5S,8S,11S,14R,17S,19aS)-11-(4-aminobutyl)-5-benzyl-8-(4-benzyloxybenzyl)-14-(1H-indol-3-ylmethyl)-4,7,10,13,16,19-hexaoxo-17-phenyloctadecahydro-3a,6,9,12,15,18-hexaazacyclopentacyclooctadecen-2-yl ester pamoic acid salt. The molecular formula of pasireotide pamoate is C 58 H 66 N 10 O 9 • C 23 H 16 O 6 and the molecular weight is 1435.58 g/mol. The structural formula is: The drug product consists of pasireotide pamoate uniformly distributed within microspheres which are made of biodegradable copolymers of poly (D,L-lactide-co-glycolide) acids (PLGA). SIGNIFOR LAR is available in a vial containing the sterile pasireotide pamoate, PLGA microspheres powder, 10 mg, 20 mg, 30 mg, 40 mg, and 60 mg to be reconstituted with the provided 2 mL sterile diluent. Each vial contains: *corresponds to 10 mg, 20 mg, 30 mg, 40 mg, and 60 mg of pasireotide base, respectively. 10 mg 20 mg 30 mg 40 mg 60 mg Pasireotide pamoate 13.71 mg* 27.42 mg* 41.13 mg* 54.84 mg* 82.26 mg* Poly(D,L-lactide-co-glycolide) [50-60:40-50] 13.15 mg 26.29 mg 39.44 mg 52.58 mg 78.87 mg Poly(D,L-lactide-co-glycolide) [50:50] 13.15 mg 26.29 mg 39.44 mg 52.58 mg 78.87 mg Each diluent prefilled syringe contains: Mannitol 90 mg Carboxymethylcellulose sodium 14 mg Poloxamer 188 4 mg Water for injections add to 2 mL structural formula
Indications & Usage
SIGNIFOR LAR is a somatostatin analog indicated for the treatment of: Patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. ( 1.1 ) Patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. ( 1.2 ) 1.1 Acromegaly SIGNIFOR LAR is indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. 1.2 Cushing's Disease SIGNIFOR LAR is indicated for the treatment of patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.
Dosage & Administration
Evaluate fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), liver enzyme tests, electrocardiogram (ECG), serum magnesium, and serum potassium prior to starting. ( 2.1 ) Optimize glucose control in patients with poorly controlled diabetes mellitus prior to starting. ( 2.1 ) Must be administered by a health care professional only by intramuscular injection in the right or left gluteus immediately after reconstitution. ( 2.2 ) Initial Dose: Acromegaly: The initial dose is 40 mg by intramuscular injection once every 4 weeks (every 28 days). ( 2.3 ) Cushing's Disease: The initial dose is 10 mg by intramuscular injection once every 4 weeks (every 28 days). ( 2.3 ) Adjust dose based on response and tolerability. ( 2.4 ) Patients with Hepatic Impairment: Child-Pugh B : Acromegaly: Recommended initial dose is 20 mg once every 4 weeks and maximum dose is 40 mg once every 4 weeks ( 2.5 , 8.6 ) Cushing's Disease: Recommended initial dose is 10 mg once every 4 weeks and maximum dose is 20 mg once every 4 weeks ( 2.5 , 8.6 ) Child-Pugh C : Avoid use in these patients ( 2.5 , 8.6 ) Follow reconstitution and administration instructions. ( 2.6 ) 2.1 Recommended Baseline Evaluations Prior to Initiation of SIGNIFOR LAR Prior to the initiation of SIGNIFOR LAR, it is recommended that patients have the following baseline evaluations: Fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) [see Warnings and Precautions (5.1)] Liver tests [see Warnings and Precautions (5.3)] Electrocardiogram (ECG), serum potassium and serum magnesium levels [see Warnings and Precautions (5.2)] Patients with poorly controlled diabetes mellitus, who have inadequate glucose control, should have anti-diabetic therapy optimized prior to starting SIGNIFOR LAR [see Warnings and Precautions (5.1)] . 2.2 Important Administration Instructions SIGNIFOR LAR must be reconstituted by a trained healthcare professional immediately before use. Illustrations on reconstitution are found in Instructions for Use [see Dosage and Administration (2.6)] . SIGNIFOR LAR must be inspected visually before use. The suspension should appear free of foreign particulates and should be homogeneous after mixing. SIGNIFOR LAR must be administered by a trained healthcare professional only by intramuscular injection in the right or left gluteus immediately after reconstitution. SIGNIFOR LAR must never be administered intravenously. 2.3 Recommended Initial Dose Acromegaly The recommended initial dose of SIGNIFOR LAR for the treatment of acromegaly is 40 mg administered by intramuscular injection once every 4 weeks (every 28 days) [see Dosage and Administration (2.6) ]. Cushing's Disease The recommended initial dose of SIGNIFOR LAR for the treatment of Cushing's disease is 10 mg administered by intramuscular injection once every 4 weeks (every 28 days) [see Dosage and Administration (2.6) ]. 2.4 Dose Adjustment and Monitoring Acromegaly The dose may be increased to a maximum of 60 mg for patients who have not normalized growth hormone (GH) and/or age and sex adjusted insulin-like growth factor-1 (IGF-1) levels after 3 months of treatment with SIGNIFOR LAR at 40 mg and who tolerate this dose. Management of SIGNIFOR LAR-related adverse reactions or over-response to treatment (age and sex adjusted IGF-1 less than the lower limit of normal) may require dose reduction. The dose may be decreased, either temporarily or permanently, by 20 mg decrements [see Warnings and Precautions (5)] . Cushing's Disease Following 4 months of treatment with the initial dose of 10 mg once every 28 days, the dose may be increased for patients who have not normalized 24-hour urinary free cortisol (UFC) and who tolerate this dose, up to a maximum dose of 40 mg once every 28 days. Management of suspected adverse reactions or over-response to treatment (e.g., cortisol levels less than the lower limit of the normal range or in the low part of the normal range in patients with symptoms suggestive of adrenal insufficiency) may require dose reduction to the previous tolerated dose, dose interruption, or drug discontinuation of SIGNIFOR LAR. For patients treated with 10 mg once every 28 days, the dose may be either interrupted or discontinued [see Warnings and Precautions (5)] . 2.5 Dose in Patients With Hepatic Impairment For patients with moderately impaired hepatic function (Child-Pugh B) [see Use in Specific Populations (8.6) ] : Acromegaly: The recommended initial dose for acromegaly patients with moderately impaired hepatic function is 20 mg once every 4 weeks and the maximum recommended dose is 40 mg once every 4 weeks. Cushing's Disease: The recommended initial dose for Cushing's disease patients with moderately impaired hepatic function is 10 mg once every 4 weeks and the maximum recommended dose is 20 mg once every 4 weeks. Avoid use in patients with severe hepatic impairment (Child-Pugh C) [see Use in Specific Populations (8.6)] . 2.6 Reconstitution and Intramuscular Injection Instructions After reconstitution of the SIGNIFOR LAR vial with the provided 2 mL diluent, the intramuscular injectable suspension will have a final concentration of: Strength per Vial Final Concentration When Reconstituted (total product strength per total volume) Final Concentration When Reconstituted (per mL) 10 mg 10 mg/2 mL 5 mg/mL 20 mg 20 mg/2 mL 10 mg/mL 30 mg 30 mg/2 mL 15 mg/mL 40 mg 40 mg/2 mL 20 mg/mL 60 mg 60 mg/2 mL 30 mg/mL The entire contents of the reconstituted solution should be administered immediately. PAY PARTICULAR ATTENTION: There are 2 critical steps in the reconstitution of SIGNIFOR LAR. Not following these 2 steps could result in failure to deliver the drug appropriately . 1) The injection kit must reach room temperature (see Step 1 in Instructions for Use) . Remove the SIGNIFOR LAR injection kit from refrigerated storage and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours. 2) After adding the diluent solution, shake the vial moderately in a horizontal direction for a minimum of 30 seconds until uniform suspension is formed (see Step 4 in Instructions for Use) . The following items are included in the injection kit : a) One vial containing SIGNIFOR LAR powder b) One prefilled syringe containing the diluent solution for reconstitution c) One vial adapter for drug product reconstitution d) One safety injection needle (20G x 1.5") Figure 1. Items Included in Injection Kit SIGNIFOR LAR suspension must only be reconstituted immediately before administration. Follow the directions in the Instructions for Use to ensure proper reconstitution of SIGNIFOR LAR before intramuscular injection. SIGNIFOR LAR should only be administered by a trained healthcare professional. Instructions for Use Step 1 Remove the SIGNIFOR LAR for injectable suspension kit from refrigerated storage. PAY PARTICULAR ATTENTION: It is essential to start the reconstitution process only after the injection kit has reached room temperature. Let the kit stand at room temperature for at least 30 minutes before starting reconstitution, but not more than 24 hours. Note: The kit can be re-refrigerated if needed. Step 2 Remove the plastic cap from the vial and clean the rubber stopper with an alcohol wipe. Remove the lid film of the vial adapter packaging, but do NOT remove the vial adapter from its packaging. Holding the vial adapter packaging, position the vial adapter on top of the vial and push it fully down so that it snaps in place. You will hear an audible "click" when the vial adapter snaps in place. Lift the packaging off the vial adapter with a vertical movement. Step 3 Remove the cap from the syringe prefilled with diluent solution and screw the syringe onto the vial adapter. Slowly push the plunger all the way down to transfer all the diluent solution in the vial. Step 4 ATTENTION: Keep the plunger pressed and shake the vial moderately in a horizontal direction for a minimum of 30 seconds so that the powder is completely suspended . Repeat moderate shaking for another 30 seconds if the powder is not completely suspended . Step 5 Turn the syringe and vial upside down, slowly pull the plunger back and draw the entire content from the vial into the syringe. Unscrew the syringe from the vial adapter. Step 6 Screw the safety injection needle onto the syringe. Pull the protective cover straight off the needle. To avoid sedimentation and maintain a uniform suspension, you may gently shake the syringe. Gently tap the syringe to remove any visible bubbles and expel them from the syringe. The reconstituted SIGNIFOR LAR is now ready for immediate administration. Step 7 SIGNIFOR LAR must only be given by intramuscular injection and NEVER intravenously. Prepare the injection site by wiping with an alcohol wipe. Insert the needle fully into the left or right gluteus at a 90° angle to the skin. Slowly pull back the plunger to check that no blood vessel has been penetrated (reposition if a blood vessel has been penetrated). Slowly depress the plunger until the syringe is empty. Withdraw the needle from the injection site and activate the safety guard (as shown in Step 8). Step 8 Activate the safety guard over the needle using 1 of the 2 methods shown: • either press the hinged section of the safety guard down onto a hard surface (Figure A), • or push the hinge forward with your finger (Figure B). An audible "click" will confirm proper activation of the safety guard. Dispose of syringe immediately in a sharps container. Any unused product or waste material should be disposed of in accordance with local requirements. Included in the injection kit: Step 1 Step 2 Remove the lid film of the vial adapter packaging, but do NOT remove the vial adapter from its packaging. Lift the packaging off the vial adapter with a vertical movement. Step 3 Slowly push the plunger all the way down to transfer all the diluent solution in the vial. Step 4 Step 5 Unscrew the syringe from the vial adapter. Step 6 Pull the protective cover straight off the needle. Step 7 Step 8 2.7 Missed Dose If a dose is missed and the patient returns prior to the next scheduled dose, a dose may be given up to but no later than 14 days prior to the next dose.
Warnings & Precautions
Hyperglycemia, Diabetes, and Ketoacidosis: Sometimes severe. Monitor glucose levels as clinically appropriate during therapy. Monitor glucose levels more frequently in the months that follow initiation or discontinuation of SIGNIFOR LAR therapy and following SIGNIFOR LAR dose adjustment. Use anti-diabetic treatment if indicated.If ketoacidosis is suspected, discontinue SIGNIFOR LAR and promptly evaluate and treat the patient. ( 2.1 , 5.1 ) Bradycardia and QT Prolongation: Use with caution in at-risk patients; evaluate ECG and electrolytes prior to dosing and periodically while on treatment. ( 2.1 , 5.2 , 7.1 ) Liver Test Elevations: Evaluate liver enzyme tests prior to and during treatment. ( 2.1 , 5.3 ) Cholelithiasis and Complications of Cholelithiasis: Monitor periodically. Discontinue if complications of cholelithiasis are suspected. ( 5.4 ) Pituitary Hormone Deficiency(ies): Monitor for occurrence periodically and treat if clinically indicated. ( 5.5 ) Steatorrhea and Malabsorption of Dietary Fats : New onset steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss may occur. If new occurrence or worsening of these symptoms are reported, evaluate for potential pancreatic exocrine insufficiency ( 5.6 ) 5.1 Hyperglycemia, Diabetes, and Ketoacidosis SIGNIFOR LAR can cause increases in blood glucose levels which are sometimes severe. There have been postmarketing cases of ketoacidosis with SIGNIFOR LAR in patients with history of diabetes and in patients without history of diabetes. In the acromegalic patient study, 5 patients naïve to drug therapy treated with SIGNIFOR LAR (2 of whom were normoglycemic at baseline) and none in the active comparator group were hospitalized for hyperglycemia (blood glucose range 359-506 mg/dL). Two additional patients who had received active comparator in the main trial and were switched to SIGNIFOR LAR in the extension trial, were hospitalized for elevated glucose levels while on SIGNIFOR LAR; one of those patients developed diabetic ketoacidosis. In the Cushing's disease study, 2 patients were hospitalized for elevated blood glucose. In clinical studies for acromegaly and Cushing's disease, SIGNIFOR LAR caused an increase in the incidence of diabetes and prediabetes. A majority of patients, including those with normal glucose tolerance, prediabetes and diabetes, experienced increased glucose levels within the first 3 months of treatment [see Adverse Reactions (6.1) ]. In the drug-naïve acromegaly study, the prevalence of diabetes increased from 30% at baseline to 60% at Month 12. In the study evaluating acromegaly patients previously treated with somatostatin analogs, the prevalence of diabetes increased from 71% at baseline to 87% at Month 6 in patients treated with SIGNIFOR LAR 40 mg, and from 60% to 84% in patients treated with SIGNIFOR LAR 60 mg. In the Cushing's disease study, the prevalence of diabetes increased from 40% at baseline to 56% at Month 12. Patients with poor baseline glycemic control are at higher risk of developing severe hyperglycemia. Assess FPG and HbA1c prior to starting treatment with SIGNIFOR LAR [see Dosage and Administration (2.1)] . In patients with poorly controlled diabetes mellitus, optimize anti-diabetic treatment before SIGNIFOR LAR initiation. Monitor blood glucose weekly for the first 3 months after initiating SIGNIFOR LAR and the first 4- to 6 weeks after dose increases. Continue monitoring thereafter, as clinically appropriate. Patients who develop significant hyperglycemia on SIGNIFOR LAR may require initiation of anti-diabetic treatment or adjustment in their current anti-diabetic treatment. The optimal treatment for the management of SIGNIFOR LAR-induced hyperglycemia is not known. If hyperglycemia cannot be controlled despite medical management, reduce the dose of SIGNIFOR LAR or discontinue SIGNIFOR LAR. Assess FPG and HbA1c after SIGNIFOR LAR discontinuation, if indicated. Patients receiving anti-diabetic treatment may require more frequent blood glucose monitoring and dose adjustment to their anti-diabetic drug therapy to mitigate the risk of hypoglycemia after discontinuing SIGNIFOR LAR. Patients who present with signs and symptoms consistent with severe metabolic acidosis should be assessed for ketoacidosis regardless of diabetes history. In some reported post-marketing cases of ketoacidosis in patients taking SIGNIFOR LAR, factors predisposing to ketoacidosis such as acute illness, infection, pancreatic disorders (e.g., pancreatic malignancy or pancreatic surgery), and alcohol abuse were present. If ketoacidosis is suspected, discontinue SIGNIFOR LAR and promptly evaluate and treat the patient. 5.2 Bradycardia and QT Prolongation Bradycardia Bradycardia has been reported with the use of SIGNIFOR LAR [see Adverse Reactions (6.1)] . Patients with cardiac disease and/or risk factors for bradycardia, such as history of clinically significant bradycardia, high-grade heart block, or concomitant use of drugs associated with bradycardia, should be monitored. Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. QT Prolongation In cardiac electrophysiology studies (i.e., thorough QT studies) with pasireotide via subcutaneous route, QT prolongation occurred at therapeutic and supra-therapeutic doses [see Clinical Pharmacology (12.2)] . In the clinical studies, a corrected QT interval (i.e., QTcF) of greater than 480 ms was reported in 6 patients and an increase in the QTcF from baseline of greater than 60 ms was reported for seven patients on SIGNIFOR LAR. No patient on SIGNIFOR LAR had a QTcF value of greater than 500 ms [see Adverse Reactions (6.1) , Clinical Pharmacology (12.2) ] . SIGNIFOR LAR should be used with caution in patients who are at significant risk of developing prolongation of the QT interval, such as those listed below: with congenital long QT prolongation with uncontrolled or significant cardiac disease including recent myocardial infarction, congestive heart failure, unstable angina or clinically significant bradycardia on anti-arrhythmic therapy or other substances that are known to lead to QT prolongation with hypokalemia and/or hypomagnesemia A baseline ECG is recommended prior to initiating therapy with SIGNIFOR LAR. Monitoring for an effect on the QT interval at the time of maximum drug concentration (21 days after injection) should be obtained in patients at risk. Hypokalemia or hypomagnesemia must be corrected prior to initiating SIGNIFOR LAR and should be monitored periodically during therapy. 5.3 Liver Test Elevations Increases in liver enzymes have been observed with SIGNIFOR LAR. In all Phase 3 acromegaly studies and across all doses, alanine aminostransferase (ALT) or aspartate aminotransferase (AST) elevations greater than 3 times the upper limit of normal (ULN) were observed in 4% of acromegaly patients and ALT or AST elevations greater than 5 times the ULN were observed in 1% of acromegaly patients treated with SIGNIFOR LAR. In the Phase 3 Cushing's disease study and across all doses, ALT or AST elevations greater than 3 times the ULN were observed in 14% of Cushing's disease patients and ALT or AST elevations greater than 5 times the ULN were observed in 5% of Cushing's disease patients treated with SIGNIFOR LAR. Assessment of liver function is recommended prior to treatment with SIGNIFOR LAR , and after the first 2- to 3 weeks, then monthly for 3 months. Thereafter, liver function should be monitored as clinically indicated. Patients who develop increased transaminase levels, should be monitored until values return to pre-treatment levels. Treatment with SIGNIFOR LAR should be discontinued if signs or symptoms suggestive of clinically significant liver impairment develop. Following discontinuation of treatment with SIGNIFOR LAR, patients should be monitored until resolution. Treatment should not be restarted, if the liver function abnormalities are suspected to be related to SIGNIFOR LAR. 5.4 Cholelithiasis and Complications of Cholelithiasis Cholelithiasis was reported in 33% of drug-naïve and 10% of inadequately controlled (40 mg dose) acromegaly patients treated with SIGNIFOR LAR in clinical trials [see Adverse Reactions (6)] . Cholelithiasis was reported in 33% of Cushing's disease patients treated with SIGNIFOR LAR. There have been postmarketing reports of cholelithiasis (gallstones) resulting in complications, including cholecystitis or cholangitis and requiring cholecystectomy in patients taking SIGNIFOR LAR. Patients should be monitored periodically. If complications of cholelithiasis are suspected, discontinue SIGNIFOR LAR and treat appropriately. 5.5 Pituitary Hormone Deficiency(ies) Suppression of anterior pituitary hormones may occur on SIGNIFOR LAR. Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. Patients should be monitored for and instructed on the signs and symptoms of adrenal insufficiency during therapy. If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . 5.6 Steatorrhea and Malabsorption of Dietary Fats New onset steatorrhea, stool discoloration and loose stools have been reported in patients receiving somatostatin analogs, including pasireotide products. Somatostatin analogs reversibly inhibit secretion of pancreatic enzymes and bile acids, which may result in malabsorption of dietary fats and subsequent symptoms of steatorrhea, loose stools, abdominal bloating, and weight loss. If new occurrence or worsening of these symptoms are reported in patients receiving SIGNIFOR LAR, evaluate patients for potential pancreatic exocrine insufficiency and manage accordingly.
Contraindications
None. None. ( 4 )
Adverse Reactions
Clinically significant adverse reactions that appear in other sections of the labeling include: Hyperglycemia, Diabetes, and Ketoacidosis [see Warnings and Precautions (5.1)] Bradycardia and QT Prolongation [see Warnings and Precautions (5.2)] Liver Test Elevations [see Warnings and Precautions (5.3)] Cholelithiasis and Complications of Cholelithiasis [see Warnings and Precautions (5.4)] Pituitary Hormone Deficiency(ies) [see Warnings and Precautions (5.5)] Steatorrhea and Malabsorption of Dietary Fats [see Warnings and Precautions (5.6) ] Adverse drug reactions associated with SIGNIFOR LAR and occurring in ≥ 20% of patients were diarrhea, cholelithiasis, hyperglycemia, and diabetes mellitus. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases Inc. at 1-888-575-8344 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. Drug-Naïve Patients With Acromegaly The data described in Table 1 are derived from an active-controlled trial in patients with acromegaly naïve to previous drug therapy [see Clinical Studies (14.1)] . The data reflect exposure of 178 patients with acromegaly to SIGNIFOR LAR for a mean duration of 43 weeks. In the overall study population, 52% were female and the average age of patients was 45 years. Table 1 presents common adverse reactions associated with SIGNIFOR LAR in this study. These adverse reactions were not present at baseline or, if present, worsened from baseline and occurred in at least 5% of patients treated with SIGNIFOR LAR. Table 1 – Adverse Reactions Occurring in Greater Than or Equal to 5% of Patients Exposed to SIGNIFOR LAR in Patients With Acromegaly Naïve to Drug Therapy a Diabetes mellitus includes the following PTs: diabetes mellitus and type 2 diabetes mellitus. b Sinus bradycardia includes the following PTs: bradycardia and sinus bradycardia. c Injection-site reaction related AEs includes the following PTs: injection-site pain, injection-site reaction, injection-site haematoma, injection-site pruritus, injection-site swelling, injection-site erythema. Adverse Reaction Type SIGNIFOR LAR (40-60 mg) % N = 178 Active Comparator % N = 180 Hyperglycemia Related Adverse Reactions Hyperglycemia 29 8 Diabetes mellitus a 26 4 Blood glucose increased 8 2 Glycosylated hemoglobin increased 6 2 Hypoglycemia 5 7 Gastrointestinal Related Adverse Reactions Diarrhea 39 45 Abdominal pain 18 22 Nausea 14 22 Abdominal distension 12 12 Vomiting 8 7 Abdominal pain upper 6 8 Hepatobiliary Related Adverse Reactions Cholelithiasis 26 36 Cardiac Related Adverse Reactions Sinus bradycardia b 10 7 Hypertension 8 7 Nervous System Related Adverse Reactions Headache 19 26 Dizziness 10 11 Skin Related Adverse Reactions Alopecia 18 19 Infections Related Adverse Reactions Nasopharyngitis 16 16 Influenza 8 4 Upper respiratory tract infection 7 3 Cough 5 8 Laboratory Related Adverse Reactions Blood creatine phosphokinase increased 13 12 Alanine aminotransferase increased 8 4 Aspartate aminotransferase increased 6 4 Lipase increased 6 7 Weight decreased 5 4 General and Injection-Site Related Adverse Reactions Fatigue 10 10 Injection-site reaction c 7 7 Musculoskeletal and Connective Tissue Related Adverse Reactions Arthralgia 10 12 Back pain 8 11 Pain in extremity 7 4 Blood Related Adverse Reactions Anemia 6 6 Other notable adverse reactions which occurred with a frequency of 5% or less for SIGNIFOR LAR were: adrenal insufficiency (3%); glucose tolerance impaired (1%); QT-prolongation (4%); blood amylase increased (2%). Patients With Acromegaly Inadequately Controlled on Other Somatostatin Analogs at Baseline The data described in Table 2 are derived from an active-controlled study in patients with acromegaly inadequately controlled at baseline on other somatostatin analogs [see Clinical Studies (14.2)] . These data reflect exposure of 63 and 62 patients to SIGNIFOR LAR 40 mg and 60 mg, respectively, for a mean duration of 24 weeks. In the overall study population, 56% were female and the average age of patients was 45 years. Table 2 presents common adverse reactions associated with SIGNIFOR LAR in this study. These common adverse reactions were not present at baseline, or if present, worsened from baseline and occurred in at least 5% of patients treated with SIGNIFOR LAR. Table 2 – Adverse Reactions Occurring in Greater Than or Equal to 5% of Patients Exposed to SIGNIFOR LAR in Patients With Acromegaly Previously Treated With Other Somatostatin Analogs a Diabetes mellitus includes the following PTs: diabetes mellitus and type 2 diabetes mellitus. Adverse Drug Reactions SIGNIFOR LAR 40 mg % N = 63 SIGNIFOR LAR 60 mg % N = 62 Active Comparators % N = 66 Hyperglycemia Related Adverse Reactions Hyperglycemia 33 30 14 Diabetes mellitus a 21 31 9 Blood glucose increased 5 7 0 Hypoglycemia 3 7 0 Gastrointestinal Related Adverse Reactions Diarrhea 16 19 5 Abdominal pain 8 8 3 Nausea 3 7 3 Hepatobiliary Related Adverse Reactions Cholelithiasis 10 13 14 Cardiac Related Adverse Reactions Atrioventricular block first degree 6 0 0 Nervous System Related Adverse Reactions Headache 14 3 5 Dizziness 8 2 3 Skin and Subcutaneous Tissue Related Adverse Reactions Alopecia 2 7 0 Infections Related Adverse Reactions Nasopharyngitis 6 11 3 Blood Related Adverse Reactions Anemia 6 3 3 Other notable adverse reactions which occurred with a frequency of 5% or less in the SIGNIFOR LAR 40 mg, SIGNIFOR LAR 60 mg arm, respectively, were adrenal insufficiency (2% and 0%) and glucose tolerance impaired (3% and 5%). Patients With Cushing's Disease The data described in Table 3 are derived from a randomized clinical study in 150 patients with Cushing's disease [see Clinical Studies (14.3)] . These data reflect exposure of 74 and 76 patients to SIGNIFOR LAR at a starting dose of 10 mg and 30 mg once every 28 days, respectively, for a mean duration of 68 weeks. In the overall study population, 79% of patients were female and the average age was 39 years at study entry. Table 3 presents common adverse reactions which were not present at baseline or, if present, worsened from baseline and occurred in at least 5% of patients treated with SIGNIFOR LAR. Table 3 – Adverse Reactions Occurring in Greater Than or Equal to 5% of Patients Exposed to SIGNIFOR LAR in Patients With Cushing's Disease a Diabetes mellitus consists of the two terms: diabetes mellitus and type 2 diabetes mellitus. b Abdominal pain includes the term abdominal pain upper. c Sinus bradycardia includes the term bradycardia. d Fatigue includes the term asthenia. Adverse Reactions Overall % N = 150 Endocrine Related Adverse Reactions Adrenal insufficiency 7 Blood cortisol decreased 5 Hyperglycemia Related Adverse Reactions Hyperglycemia 47 Diabetes mellitus a 27 Hypoglycemia 15 Blood glucose increased 9 Glycosylated hemoglobin (HbA1C) increased 5 Gastrointestinal Related Adverse Reactions Diarrhea 39 Nausea 21 Abdominal pain b 23 Constipation 7 Abdominal distension 5 Flatulence 5 Vomiting 5 Hepatobiliary Related Adverse Reactions Cholelithiasis 33 Gamma-glutamyltransferase increased 9 Alanine aminotransferase increased 7 Cardiac Related Adverse Reactions Hypertension 15 Hypotension 6 Sinus bradycardia c 5 General Related Adverse Reactions Fatigue d 27 Edema peripheral 14 Musculoskeletal and Connective Tissue Related Adverse Reactions Back pain 11 Arthralgia 8 Pain in extremity 7 Myalgia 5 Metabolism and Nutrition Related Adverse Reactions Decreased appetite 10 Hyperuricemia 7 Hypercholesterolemia 6 Blood Related Adverse Reactions Anemia 5 Other adverse reactions which occurred at a frequency less than 5% were cholestasis (4%), glucose tolerance impaired (3%), aspartate aminotransferase increased (3%), vomiting (3%), lipase increased (3%), injection-site reactions (2%), ECG QT prolonged (1%), cholecystitis (1%), amylase increased (1%), and prothrombin time prolonged (1%). Hyperglycemia The average FPG levels in patients with acromegaly naïve to drug therapy study [see Clinical Studies (14.1)] across visits is shown in Figure 2 below. Figure 2. Mean Fasting Plasma Glucose (mg/dL) By Visit in the Study of Patients With Acromegaly Naïve to Drug Therapy Numbers of patients with a glucose value at the given timepoint in the SIGNIFOR LAR/Active comparator arms are displayed as xxx/xxx on the x axis. Pancreatic Enzyme Elevation and Pancreatitis Asymptomatic elevations in lipase and alpha amylase were observed in 30% and 20% of patients receiving SIGNIFOR LAR in the drug naïve study in acromegaly, and in 1% and 3% of patients receiving SIGNIFOR LAR in the study of acromegaly patients previously treated. In the drug-naïve study, 2 acromegaly patients receiving SIGNIFOR LAR developed pancreatitis. In the Cushing's disease study, increased lipase was observed in 4% of patients, and 1 patient developed pancreatitis. Pancreatitis is a potential adverse reaction associated with the use of SIGNIFOR LAR due to the association between cholelithiasis and acute pancreatitis. Figure 2. Mean Fasting Plasma Glucose (mg/dL) By Visit in the Study of Patients With Acromegaly Naïve to Drug Therapy* 6.2 Postmarketing Experience Additional adverse reactions have been identified during post-approval use of SIGNIFOR LAR. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cholelithiasis resulting in complications, including cholecystitis and cholangitis, which have sometimes required cholecystectomy
Drug Interactions
Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. ( 5.2 , 7.1 ) Cyclosporine: Consider additional monitoring. ( 7.2 ) Bromocriptine: Consider bromocriptine dose reduction. ( 7.2 ) 7.1 Effect of Other Drugs on SIGNIFOR LAR Drugs That Prolong QT Co-administration of drugs that prolong the QT interval with SIGNIFOR LAR may have additive effects on the prolongation of the QT interval. Monitoring effects on the QT interval at 21 days is recommended [see Warnings and Precautions (5.2)] . 7.2 Effect of SIGNIFOR LAR on Other Drugs Cyclosporine Concomitant administration of cyclosporine with SIGNIFOR LAR may decrease the relative bioavailability of cyclosporine and, therefore, dose adjustment of cyclosporine to maintain therapeutic levels may be necessary. Bromocriptine Co-administration of SIGNIFOR LAR with bromocriptine may increase the blood levels of bromocriptine. Dose reduction of bromocriptine may be necessary.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.